CN102766605A - 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途 - Google Patents

重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途 Download PDF

Info

Publication number
CN102766605A
CN102766605A CN201010556188XA CN201010556188A CN102766605A CN 102766605 A CN102766605 A CN 102766605A CN 201010556188X A CN201010556188X A CN 201010556188XA CN 201010556188 A CN201010556188 A CN 201010556188A CN 102766605 A CN102766605 A CN 102766605A
Authority
CN
China
Prior art keywords
piv
genome
antigenome
chimeric
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201010556188XA
Other languages
English (en)
Chinese (zh)
Inventor
B·R·摩菲
P·L·克林斯
A·C·施密特
A·P·德宾
M·H·斯奇雅多普罗斯
陶涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/459,062 external-priority patent/US7250171B1/en
Priority claimed from US09/458,813 external-priority patent/US7314631B1/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN102766605A publication Critical patent/CN102766605A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201010556188XA 1999-12-10 2000-12-08 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途 Pending CN102766605A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17019599P 1999-12-10 1999-12-10
US09/458,813 1999-12-10
US60/170,195 1999-12-10
US09/459,062 1999-12-10
US09/459,062 US7250171B1 (en) 1997-05-23 1999-12-10 Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US09/458,813 US7314631B1 (en) 1997-05-23 1999-12-10 Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN00805939A Division CN1347453A (zh) 1999-12-10 2000-12-08 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和病症的用途

Publications (1)

Publication Number Publication Date
CN102766605A true CN102766605A (zh) 2012-11-07

Family

ID=27389780

Family Applications (2)

Application Number Title Priority Date Filing Date
CN00805939A Pending CN1347453A (zh) 1999-12-10 2000-12-08 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和病症的用途
CN201010556188XA Pending CN102766605A (zh) 1999-12-10 2000-12-08 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN00805939A Pending CN1347453A (zh) 1999-12-10 2000-12-08 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和病症的用途

Country Status (8)

Country Link
EP (1) EP1179054A2 (enExample)
JP (1) JP4795597B2 (enExample)
CN (2) CN1347453A (enExample)
AU (1) AU785148B2 (enExample)
CA (1) CA2362685A1 (enExample)
IL (1) IL144831A0 (enExample)
MX (1) MXPA01008108A (enExample)
WO (1) WO2001042445A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110996998A (zh) * 2017-05-29 2020-04-10 美利坚合众国- 由健康及人类服务部部长代表 表达rsv g的重组嵌合牛/人副流感病毒3及其用途
CN112534056A (zh) * 2018-06-27 2021-03-19 麦迪卡格公司 流感病毒血凝素突变体
CN112771619A (zh) * 2018-08-28 2021-05-07 皇家飞利浦有限公司 用于评估基因组比对基础的方法
CN113999292A (zh) * 2021-10-27 2022-02-01 中国农业大学 靶向呼吸道病毒属病毒的多肽抑制剂

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
CN1524088B (zh) 2001-01-19 2012-11-07 维洛诺瓦蒂夫公司 在易感哺乳动物中引起呼吸道疾病的病毒
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
EP2100955A3 (en) 2001-11-21 2009-12-02 The United States of America, represented by The Secretary, Dept. of Health and Human Services Attenuated mutants of human parainfluenza virus type 1 (HPIV1)
TWI405851B (zh) 2002-02-21 2013-08-21 Medimmune Llc 間質肺病毒株及其作為疫苗調配物及作為表現抗原性序列之載體之應用
AU2003247777B2 (en) 2002-07-01 2008-09-18 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance
WO2004027037A2 (en) 2002-09-18 2004-04-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS
WO2005014626A2 (en) 2003-02-28 2005-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
EP2494986A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2004113517A2 (en) 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
US8293517B2 (en) 2005-05-11 2012-10-23 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in Pseudomonas aeruginosa
EP1899483A4 (en) 2005-05-11 2009-02-11 Univ Wayne State NEW TARGETS FOR THE IDENTIFICATION OF ANTIBIOTICS, NOT SENSITIVE TO ANTIBIOTIC RESISTANCE
JP4905649B2 (ja) * 2006-03-08 2012-03-28 国立大学法人 長崎大学 魚用ワクチン、その製造方法、および魚類感染症の予防方法
JP4892296B2 (ja) 2006-08-24 2012-03-07 川崎製薬株式会社 魚類のエドワジェラ症及び連鎖球菌症用ワクチン
US8362203B2 (en) 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
SG178885A1 (en) 2009-08-24 2012-04-27 Baylor College Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
AU2013212097B2 (en) 2012-01-24 2017-01-12 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
CN103773803A (zh) * 2014-01-23 2014-05-07 中国农业科学院特产研究所 表达猪o型口蹄疫病毒vp1蛋白的重组牛副流感病毒载体
CN113811328A (zh) * 2019-03-25 2021-12-17 贝勒医学院 多呼吸道病毒抗原特异性t细胞及其制备方法和治疗上的使用方法
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用
JP2025518078A (ja) 2022-05-25 2025-06-12 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 低減した抗ベクター抗原性を有するワクチン
WO2025106787A1 (en) 2023-11-17 2025-05-22 Sanofi Pasteur Inc. Trehalose vaccine formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053078A1 (en) * 1997-05-23 1998-11-26 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2378661A1 (en) * 1999-07-09 2001-01-18 Alexander C. Schmidt Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053078A1 (en) * 1997-05-23 1998-11-26 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110996998A (zh) * 2017-05-29 2020-04-10 美利坚合众国- 由健康及人类服务部部长代表 表达rsv g的重组嵌合牛/人副流感病毒3及其用途
CN112534056A (zh) * 2018-06-27 2021-03-19 麦迪卡格公司 流感病毒血凝素突变体
CN112771619A (zh) * 2018-08-28 2021-05-07 皇家飞利浦有限公司 用于评估基因组比对基础的方法
CN113999292A (zh) * 2021-10-27 2022-02-01 中国农业大学 靶向呼吸道病毒属病毒的多肽抑制剂

Also Published As

Publication number Publication date
WO2001042445A3 (en) 2001-11-29
IL144831A0 (en) 2002-06-30
MXPA01008108A (es) 2004-11-12
AU2073101A (en) 2001-06-18
AU785148B2 (en) 2006-10-05
WO2001042445A2 (en) 2001-06-14
CN1347453A (zh) 2002-05-01
JP2003516148A (ja) 2003-05-13
EP1179054A2 (en) 2002-02-13
CA2362685A1 (en) 2001-06-14
JP4795597B2 (ja) 2011-10-19

Similar Documents

Publication Publication Date Title
US7192593B2 (en) Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
AU785148B2 (en) Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
JP4237268B2 (ja) クローン化されたヌクレオチド配列からの弱毒化パラインフルエンザウィルスワクチンの製造
US7951383B2 (en) Attenuated parainfluenza virus (PIV) vaccines
CN1871355B (zh) 从cDNA中回收非节段性负链RNA病毒的改进方法
CN100491531C (zh) 通过缺失或消除非必需基因而减毒的重组副流感病毒疫苗
AU2009202359A1 (en) Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP4813711B2 (ja) 弱毒ヒト−ウシキメラ−パラインフルエンザウイルス（ｐｉｖ）ワクチン
US7208161B1 (en) Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US7250171B1 (en) Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US7314631B1 (en) Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
AU2007203671B2 (en) Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121107